Mabion (WAR:MAB) Institutional Ownership: 0.01% (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:MAB Mabion SA WAR:MAB
31 GF Score
Price zł7.37
GF Value zł2.07
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Mabion Institutional Ownership?

Mabion WAR:MAB +0.55% 31 Institutional Ownership is 0.01% as of Jul. 26, 2026. GuruFocus rates WAR:MAB with a GF Score™ of 31/100 and a GF Value™ of zł2.07 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Mabion's institutional ownership is 0.01%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Mabion's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Mabion's Float Percentage Of Total Shares Outstanding is 0.00%.

Mabion Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Mabion's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mabion Institutional Ownership Chart

Mabion Historical Data

The historical data trend for Mabion can be seen below:

2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2025-03-31 2025-04-30
Institutional Ownership 0.22 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.01 0.01
WAR:MAB
31GF Score
Mabion SA WAR:MAB
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mabion Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.01% mean?
Mabion (WAR:MAB) has a Institutional Ownership of 0.01% as of Jul. 26, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Mabion and its competitors.
Is Mabion's Institutional Ownership too high?
Mabion's current Institutional Ownership is 0.01%. Overall, Mabion has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mabion's Institutional Ownership compare to VRTX and REGN?
Mabion's Institutional Ownership of 0.01% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Mabion and its competitors. Mabion's current Institutional Ownership is 0.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mabion stock overvalued right now?
Based on GuruFocus' analysis, Mabion (WAR:MAB) is currently considered Significantly Overvalued. The stock's GF Value™ is zł2.07, compared to a current price of zł7.37 — trading 256% above its estimated fair value. The current Institutional Ownership is 0.01%. Mabion's overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Mabion (WAR:MAB), the current Institutional Ownership is 0.01% as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mabion (WAR:MAB) Overvalued in 2026?

Based on GuruFocus' analysis, Mabion stock appears to be overvalued. The current stock price of zł7.37 is trading 256% above its estimated GF Value™ of zł2.07. GuruFocus considers Mabion to be Significantly Overvalued.

Key valuation signals for WAR:MAB:

  • Institutional Ownership: 0.01%
  • GF Value™: zł2.07 vs. price of zł7.37 (256% above fair value)
  • GF Score™: 31/100 with 4 warning signs

No single metric tells the full story. See the WAR:MAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mabion Business Description

Other Exchanges 272:Germany
Address ul. Gen. Mariana Langiewicza 60, Konstantynow Lodzki, POL, 95-050
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.
31GF Score

Get the complete analysis for WAR:MAB

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł7.37
Price
zł2.07
GF Value